Search

Your search keyword '"Pantazis, Caroline B."' showing total 3 results
Start Over Author "Pantazis, Caroline B." Publisher cell press
3 results on '"Pantazis, Caroline B."'

1. Harnessing diversity to study Alzheimer's disease: A new iPSC resource from the NIH CARD and ADNI.

Author

Screven, Laurel A., Pantazis, Caroline B., Andersh, Katherine M., Hong, Samantha, Vitale, Dan, Lara, Erika, Ku, Ray Yueh, Heutink, Peter, Meyer, Jason, Faber, Kelley, Nho, Kwangsik, Saykin, Andrew J., Foroud, Tatiana M., Nalls, Mike A., Blauwendraat, Cornelis, Singleton, Andrew, and Narayan, Priyanka S.

Subjects
*ALZHEIMER'S disease, *PLURIPOTENT stem cells, *DISEASE progression, *CELL lines
Abstract

The iDA Project (iPSCs to Study Diversity in Alzheimer's and Alzheimer's Disease-related Dementias) is generating 200 induced pluripotent stem cell lines from Alzheimer's Disease Neuroimaging Initiative participants. These lines are sex balanced, include common APOE genotypes, span disease stages, and are ancestrally diverse. Cell lines and characterization data will be shared openly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. A reference human induced pluripotent stem cell line for collaborative studies

Author

Pantazis, Caroline B, Yang, Andrian, Lara, Erika, McDonough, Justin A, Blauwendraat, Cornelis, Peng, Lirong, Oguro, Hideyuki, Kanaujiya, Jitendra, Zou, Jizhong, Sebesta, David, Pratt, Gretchen, Cross, Erin, Blockwick, Jeffrey, Buxton, Philip, Kinner-Bibeau, Lauren, Medura, Constance, Tompkins, Christopher, Hughes, Stephen, Santiana, Marianita, Faghri, Faraz, Nalls, Mike A, Vitale, Daniel, Ballard, Shannon, Qi, Yue A, Ramos, Daniel M, Anderson, Kailyn M, Stadler, Julia, Narayan, Priyanka, Papademetriou, Jason, Reilly, Luke, Nelson, Matthew P, Aggarwal, Sanya, Rosen, Leah U, Kirwan, Peter, Pisupati, Venkat, Coon, Steven L, Scholz, Sonja W, Priebe, Theresa, Ottl, Miriam, Dong, Jian, Meijer, Marieke, Janssen, Lara JM, Lourenco, Vanessa S, van der Kant, Rik, Crusius, Dennis, Paquet, Dominik, Raulin, Ana-Caroline, Bu, Guojun, Held, Aaron, Wainger, Brian J, Gabriele, Rebecca MC, Casey, Jackie M, Wray, Selina, Abu-Bonsrah, Dad, Parish, Clare L, Beccari, Melinda S, Cleveland, Don W, Li, Emmy, Rose, Indigo VL, Kampmann, Martin, Aristoy, Carles Calatayud, Verstreken, Patrik, Heinrich, Laurin, Chen, Max Y, Schule, Birgitt, Dou, Dan, Holzbaur, Erika LF, Zanellati, Maria Clara, Basundra, Richa, Deshmukh, Mohanish, Cohen, Sarah, Khanna, Richa, Raman, Malavika, Nevin, Zachary S, Matia, Madeline, Van Lent, Jonas, Timmerman, Vincent, Conklin, Bruce R, Chase, Katherine Johnson, Zhang, Ke, Funes, Salome, Bosco, Daryl A, Erlebach, Lena, Welzer, Marc, Kronenberg-Versteeg, Deborah, Lyu, Guochang, Arenas, Ernest, Coccia, Elena, Sarrafha, Lily, Ahfeldt, Tim, Marioni, John C, Skarnes, William C, Cookson, Mark R, Ward, Michael E, and Merkle, Florian T

Subjects
Science & Technology, Cell Biology, DOPAMINE NEURONS, RISK LOCI, GENE, DISEASE, DIRECTIONAL GENOMIC HYBRIDIZATION, COPY NUMBER, DIFFERENTIATION, Cell & Tissue Engineering, HETEROGENEITY, Life Sciences & Biomedicine, A-BETA, GENERATION
Abstract

Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines makes it challenging to replicate key findings and integrate data across research groups. To address this issue, we sub-cloned candidate human iPSC lines and deeply characterized their genetic properties using whole genome sequencing, their genomic stability upon CRISPR-Cas9-based gene editing, and their phenotypic properties including differentiation to commonly used cell types. These studies identified KOLF2.1J as an all-around well-performing iPSC line. We then shared KOLF2.1J with groups around the world who tested its performance in head-to-head comparisons with their own preferred iPSC lines across a diverse range of differentiation protocols and functional assays. On the strength of these findings, we have made KOLF2.1J and its gene-edited derivative clones readily accessible to promote the standardization required for large-scale collaborative science in the stem cell field. ispartof: CELL STEM CELL vol:29 issue:12 pages:1685-+ ispartof: location:United States status: published

Published
2022

3. A reference human induced pluripotent stem cell line for large-scale collaborative studies.

Author

Pantazis CB, Yang A, Lara E, McDonough JA, Blauwendraat C, Peng L, Oguro H, Kanaujiya J, Zou J, Sebesta D, Pratt G, Cross E, Blockwick J, Buxton P, Kinner-Bibeau L, Medura C, Tompkins C, Hughes S, Santiana M, Faghri F, Nalls MA, Vitale D, Ballard S, Qi YA, Ramos DM, Anderson KM, Stadler J, Narayan P, Papademetriou J, Reilly L, Nelson MP, Aggarwal S, Rosen LU, Kirwan P, Pisupati V, Coon SL, Scholz SW, Priebe T, Öttl M, Dong J, Meijer M, Janssen LJM, Lourenco VS, van der Kant R, Crusius D, Paquet D, Raulin AC, Bu G, Held A, Wainger BJ, Gabriele RMC, Casey JM, Wray S, Abu-Bonsrah D, Parish CL, Beccari MS, Cleveland DW, Li E, Rose IVL, Kampmann M, Calatayud Aristoy C, Verstreken P, Heinrich L, Chen MY, Schüle B, Dou D, Holzbaur ELF, Zanellati MC, Basundra R, Deshmukh M, Cohen S, Khanna R, Raman M, Nevin ZS, Matia M, Van Lent J, Timmerman V, Conklin BR, Johnson Chase K, Zhang K, Funes S, Bosco DA, Erlebach L, Welzer M, Kronenberg-Versteeg D, Lyu G, Arenas E, Coccia E, Sarrafha L, Ahfeldt T, Marioni JC, Skarnes WC, Cookson MR, Ward ME, and Merkle FT

Subjects
Humans, Cell Differentiation, Gene Editing, Biological Assay, Induced Pluripotent Stem Cells
Abstract

Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines makes it challenging to replicate key findings and integrate data across research groups. To address this issue, we sub-cloned candidate human iPSC lines and deeply characterized their genetic properties using whole genome sequencing, their genomic stability upon CRISPR-Cas9-based gene editing, and their phenotypic properties including differentiation to commonly used cell types. These studies identified KOLF2.1J as an all-around well-performing iPSC line. We then shared KOLF2.1J with groups around the world who tested its performance in head-to-head comparisons with their own preferred iPSC lines across a diverse range of differentiation protocols and functional assays. On the strength of these findings, we have made KOLF2.1J and its gene-edited derivative clones readily accessible to promote the standardization required for large-scale collaborative science in the stem cell field., Competing Interests: Declaration of interests S.W.S. is on the scientific advisory council of the Lewy Body Dementia Association and the MSA Coalition. S.W.S. is an editorial board member for the Journal of Parkinson Disease and JAMA Neurology. S.W.S. received research support from Cerevel Therapeutics. M.K. serves on the scientific advisory boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector and is a consultant to Modulo Bio and Recursion Therapeutics. Participation by researchers from Data Tecnica International, LLC in this project was part of a competitive contract awarded to Data Tecnica International, LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc. E.A. is founder, shareholder, and scientific advisor of Cholestenix, Ltd., (Published by Elsevier Inc.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results